Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

Oncologist - United States
doi 10.1634/theoncologist.2019-0094
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Oncologist
Cancer ResearchMedicineOncology
2018English

Prognostic Value of Red Blood Cell Distribution Width in Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death-1 Antibody

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2018English

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Journal of the American Academy of Dermatology
Dermatology
2016English

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

British Journal of Cancer
Cancer ResearchOncology
2015English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?

Cancer cytopathology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy